-
Mashup Score: 3Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer - 16 day(s) ago
Objectives Long-term follow-up of patients treated with trastuzumab largely focuses on those with reduced left ventricular ejection fraction (LVEF) on treatment completion. This study sought to evaluate the prevalence of cardiovascular risk factors, overt cardiovascular disease and cardiac imaging abnormalities using cardiac magnetic resonance (CMR), in participants with normal LVEF on completion of trastuzumab±anthracycline therapy at least 5 years previously. Methods Participants with human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab±anthracycline ≥5 years previously were identified from a clinical database. All participants had normal LVEF prior to, and on completion of, treatment. Participants underwent clinical cardiovascular evaluation, ECG, cardiac biomarker evaluation and CMR. Left ventricular systolic dysfunction (LVSD) was defined as LVEF <50%. Results Forty participants were recruited between 15 March 2021 and 19 July 2022. Median time
Source: heart.bmj.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 4Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer - 29 day(s) ago
Objectives Long-term follow-up of patients treated with trastuzumab largely focuses on those with reduced left ventricular ejection fraction (LVEF) on treatment completion. This study sought to evaluate the prevalence of cardiovascular risk factors, overt cardiovascular disease and cardiac imaging abnormalities using cardiac magnetic resonance (CMR), in participants with normal LVEF on completion of trastuzumab±anthracycline therapy at least 5 years previously. Methods Participants with human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab±anthracycline ≥5 years previously were identified from a clinical database. All participants had normal LVEF prior to, and on completion of, treatment. Participants underwent clinical cardiovascular evaluation, ECG, cardiac biomarker evaluation and CMR. Left ventricular systolic dysfunction (LVSD) was defined as LVEF <50%. Results Forty participants were recruited between 15 March 2021 and 19 July 2022. Median time
Source: heart.bmj.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer - 1 month(s) ago
Objectives Long-term follow-up of patients treated with trastuzumab largely focuses on those with reduced left ventricular ejection fraction (LVEF) on treatment completion. This study sought to evaluate the prevalence of cardiovascular risk factors, overt cardiovascular disease and cardiac imaging abnormalities using cardiac magnetic resonance (CMR), in participants with normal LVEF on completion of trastuzumab±anthracycline therapy at least 5 years previously. Methods Participants with human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab±anthracycline ≥5 years previously were identified from a clinical database. All participants had normal LVEF prior to, and on completion of, treatment. Participants underwent clinical cardiovascular evaluation, ECG, cardiac biomarker evaluation and CMR. Left ventricular systolic dysfunction (LVSD) was defined as LVEF <50%. Results Forty participants were recruited between 15 March 2021 and 19 July 2022. Median time
Source: heart.bmj.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer - 1 month(s) ago
Objectives Long-term follow-up of patients treated with trastuzumab largely focuses on those with reduced left ventricular ejection fraction (LVEF) on treatment completion. This study sought to evaluate the prevalence of cardiovascular risk factors, overt cardiovascular disease and cardiac imaging abnormalities using cardiac magnetic resonance (CMR), in participants with normal LVEF on completion of trastuzumab±anthracycline therapy at least 5 years previously. Methods Participants with human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab±anthracycline ≥5 years previously were identified from a clinical database. All participants had normal LVEF prior to, and on completion of, treatment. Participants underwent clinical cardiovascular evaluation, ECG, cardiac biomarker evaluation and CMR. Left ventricular systolic dysfunction (LVSD) was defined as LVEF <50%. Results Forty participants were recruited between 15 March 2021 and 19 July 2022. Median time
Source: heart.bmj.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer - 2 month(s) ago
Objectives Long-term follow-up of patients treated with trastuzumab largely focuses on those with reduced left ventricular ejection fraction (LVEF) on treatment completion. This study sought to evaluate the prevalence of cardiovascular risk factors, overt cardiovascular disease and cardiac imaging abnormalities using cardiac magnetic resonance (CMR), in participants with normal LVEF on completion of trastuzumab±anthracycline therapy at least 5 years previously. Methods Participants with human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab±anthracycline ≥5 years previously were identified from a clinical database. All participants had normal LVEF prior to, and on completion of, treatment. Participants underwent clinical cardiovascular evaluation, ECG, cardiac biomarker evaluation and CMR. Left ventricular systolic dysfunction (LVSD) was defined as LVEF <50%. Results Forty participants were recruited between 15 March 2021 and 19 July 2022. Median time
Source: heart.bmj.comCategories: General Medicine News, CardiologistsTweet
“Our findings reinforce the relevance of comprehensive evaluation of #cardiovascular risk factors following completion of #cancer therapy, in addition to LVEF assessment.” Cardiovascular sequelae of trastuzumab & anthracycline in breast cancer @Heart_BMJ https://t.co/u2hAyKQVTM